A normal diffusing capacity of the lungs for carbon monoxide is rare in incidental pulmonary arterial hypertension in systemic sclerosis: Data from the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma cohort

Abstract

Objective:

Our purpose was to determine the frequency of normal diffusing capacity for carbon monoxide defined as ⩾70% predicted, in those diagnosed with pulmonary arterial hypertension in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma cohort. We compared those with normal diffusing capacity for carbon monoxide to those with reduced diffusing capacity for carbon monoxide <70% in order to better clarify the role of pulmonary function testing as a screening test for pulmonary arterial hypertension and to better understand this population.

Methods:

Entry criteria included a right heart catheterization with mean pulmonary artery pressure ⩾25 mm Hg and pulmonary capillary wedge pressure ⩽15 mm Hg. Demographics, echocardiogram variables, B-type natriuretic peptide levels, right heart catheterization findings, and survival were described for both groups.

Results:

Of (n = 202), 11 (5.4%) had a diffusing capacity for carbon monoxide of ⩾70% versus 191 (94.6%) who had a diffusing capacity for carbon monoxide <70%. There were no identified statistical differences between the groups. Left atrium size was 4.1 cm in the normal diffusing capacity for carbon monoxide patients compared to 3.7 cm in the low diffusing capacity for carbon monoxide group but did not reach statistical significance. There were no statistically significant differences in survival. On repeat testing, seven patients subsequently developed a diffusing capacity for carbon monoxide <70%.

Conclusion:

Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma data suggest that it is very rare for a patient to develop pulmonary arterial hypertension with a preserved diffusing capacity for carbon monoxide. The data support the importance of obtaining diffusing capacity for carbon monoxide and that a patient with a normal diffusing capacity for carbon monoxide while suspected to have systemic sclerosis-pulmonary arterial hypertension should be considered critically. Diffusing capacity for carbon monoxide >70% was present in too few patients to find significant differences in B-type natriuretic peptide and atrium size. Future research should seek to confirm abnormal B-type natriuretic peptide, increased left atrium size, and other evidence of myocardial involvement on diffusing capacity for carbon monoxide.

Keywords

Systemic sclerosis pulmonary arterial hypertension diffusion capacity for carbon monoxide cardiac manifestations of systemic sclerosis

Get full access to this article

View all access options for this article.

References

Gryglewski

Botting

Vane

. Mediators produced by the endothelial cell. Hypertension 1988; 12(6): 530–548.

Kourembanas

McQuillan

Leung

et al . Nitric oxide regulates the expression of vasoconstrictors and growth factors by vascular endothelium under both normoxia and hypoxia. J Clin Invest 1993; 92(1): 99–104.

Rabquer

Koch

. Angiogenesis and vasculopathy in systemic sclerosis: evolving concepts. Curr Rheumatol Rep 2012; 14: 56–63.

Steen

Medsger

. Changes in causes of death in systemic sclerosis, 1972–2002. Ann Rheum Dis 2007; 66(7): 940–944.

Steen

Denton

Pope

et al . Digital ulcers: overt vascular disease in systemic sclerosis. Rheumatology (Oxford) 2009; 48(Suppl. 3): iii19–iii24.

Hinchcliff

Fischer

Schiopu

et al .; PHAROS Investigators. Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS): baseline characteristics and description of study population. J Rheumatol 2011;38: 2172–2179.

Valentini

Iudici

Walker

et al . The European Scleroderma Trials and Research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: derivation and validation of a preliminarily revised EUSTAR activity index. Ann Rheum Dis 2017; 76(1): 270–276.

Medsger

Jr Silman

Steen

et al . A disease severity scale for systemic sclerosis: development and testing. J Rheumatol 1999; 26(10): 2159–2167.

Harel

Hudson

Iliescu

et al . Summed and weighted summary scores for the Medsger disease severity scale compared with the physician’s global assessment of disease severity in systemic sclerosis. J Rheumatol 2016; 43(8): 1510–1518.

10.

Van den Hoogen

Khanna

Fransen

et al . 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against rheumatism collaborative initiative. Arthritis Rheum 2013; 65(11): 2737–2747.

11.

Coghlan

Denton

Grünig

et al . Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Ann Rheum Dis 2014; 73(7): 1340–1349.

12.

Nakanishi

; and European Society of Cardiology; European Respiratory Society. 2009 ESC/ERS pulmonary hypertension guidelines and connective tissue disease. Allergol Int 2011; 60(4): 419–424.

13.

Quinlivan

Thakkar

Stevens

et al . Cost savings with a new screening algorithm for pulmonary arterial hypertension in systemic sclerosis. Intern Med J 2015; 45(11): 1134–1140.

14.

Hao

Thakkar

Stevens

et al . A comparison of the predictive accuracy of three screening models for pulmonary arterial hypertension in systemic sclerosis. Arthritis Res Ther 2015; 17: 7.

15.

Meune

Avouac

Airò

et al . Prediction of pulmonary hypertension related to systemic sclerosis by an index based on simple clinical observations. Arthritis Rheum 2011; 63(9): 2790–2796.

16.

Mathai

. The wisdom of the PHAROS. J Rheumatol 2011; 38(10): 2089–2091.

17.

Mukerjee

St George

Knight

et al . Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis. Rheumatology 2004; 43(4): 461–466.

18.

Hachulla

Gressin

Guillevin

et al . Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arth Rheum 2005; 52: 3792–3800.

19.

Meune

Khanna

Aboulhosn

et al . A right ventricular diastolic impairment is common in systemic sclerosis and is associated with other target-organ damage. Semin Arthritis Rheum 2016; 45(4): 439–445.

20.

Bissell

Md Yusof

Buch

. Primary myocardial disease in scleroderma—a comprehensive review of the literature to inform the UK Systemic Sclerosis Study Group cardiac working group. Rheumatology (Oxford) 2016; 56: 882–895.